N-methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10455-10463

  Bautista Aguilera, Oscar M ^a   Samadi, Abdelouahid ^a   Chioua, Mourad ^a   Nikolic, Katarina ^b   Filipic, Slavica ^b   Agbaba, Danica ^b   Soriano, Elena ^c   De Andrés, Lucía ^d   Rodríguez Franco, María Isabel ^d   Alcaro, Stefano ^e   Ramsay, Rona R ^f   Ortuso, Francesco ^e   Yañez, Matilde ^g   Marco Contelles, José ^a  

^a INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CSIC   (Spain)

^d INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f UNIVERSITY OF ST ANDREWS   (United Kingdom)

^g UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; CHOLINESTERASE INHIBITOR; CLORGYLINE; DONEPEZIL; INDOLE DERIVATIVE; LADOSTIGIL; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; N METHYL N [[1 METHYL 5 [3 [1 (2 METHYLBENZYL)PIPERIDIN 4 YL]PROPOXY] 1H INDOL 2 YL]METHYL]PROP 2 YN 1 AMINE; N [[5 [3 (1 BENZYLPIPERIDIN 4 YL)PROPOXY] 1 METHYL 1H INDOL 2 YL]METHYL] N METHYLPROP 2 YN 1 AMINE; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; AMINE OXIDASE (FLAVIN CONTAINING); CHOLINESTERASE; MONOAMINE OXIDASE INHIBITOR; N-METHYL-N-((1-METHYL-5-(3-(1-(2-METHYLBENZYL)PIPERIDIN-4-YL)PROPOXY)-1H-INDOL-2-YL)METHYL)PROP-2-YN-1-AMINE; PIPERIDINE DERIVATIVE;

ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; HUMAN; IC50; MOLECULAR MODEL; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; ANIMAL; BRAIN; CELL MEMBRANE PERMEABILITY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; SWINE; SYNTHESIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; INDOLES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PIPERIDINES; SWINE;

EID: 84920175684     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501501a     Document Type: Article

References (57)

1. Castellani, R. J.; Rolston, R. K.; Smith, M. A. Alzheimer disease Dis. Month 2010, 56, 484-546
2. Reitz, C.; Brayne, C.; Mayeux, R. Epidemiology of Alzheimer disease Nature Rev. Neurol. 2011, 7, 137-152
3. Goedert, M.; Spillantini, M. G. A century of Alzheimer's disease Science 2006, 314, 777-781
4. Terry, R. D.; Gonatas, N. K.; Weiss, M. Ultrastructural studies in Alzheimer's presenile dementia Ann. J. Pathol. 1964, 44, 269-297
5. Grundke-Iqbal, I.; Iqbal, K.; Tung, Y. C.; Quinlan, M.; Wisniewski, H. M.; Binder, L.I. Abnormal phosphorylation of the microtubule-associated protein t (tau) in Alzheimer cystoskeletal pathology Proc. Natl. Acad. Sci. U. S. A. 1986, 93, 4913-4917
6. Rosini, M.; Simoni, E.; Milelli, A.; Minarini, A.; Melchiorre, C. Oxidative stress in Alzheimer's disease: Are we connecting the dots? J. Med. Chem. 2014, 57, 2821-2831
7. Perry, E. K.; Tomlinson, B. E.; Blesseed, G.; Bergmann, K.; Gibson, P. H.; Perry, R. H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia Br. Med. J. 1978, 2, 1457-1459
8. Talesa, V. N. Acetylcholinesterase in Alzheimer's disease Mech. Ageing Dev. 2001, 122, 1961-1969
9. Terry, A. V.; Buccafusco, J. J.; Wilson, C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets Behav. Brain Res. 2008, 195, 30-38
10. Youdim, M. B. H.; Finberg, J. P. M.; Tipton, K. F. Monoamine oxidase. In Handbook of Experimental Pharmacology; Tredelenburg, U.; Weiner, N., Eds.; Springer-Verlag: Berlin, 1988; Vol. 20, pp 119-192.
11. Johnston, J. P. Some observations upon a new inhibitor of monoamine oxidasein brain tissue Biochem. Pharmacol. 1968, 17, 1285-1297
12. Grimsby, J.; Lan, N. C.; Neve, R.; Chen, K.; Shih, J. C. Tissue distribution of human monoamine oxidase A and B mRNA J. Neurochem. 1990, 55, 1166-1169
13. Harfenist, H.; Heuseur, D. J.; Joyner, C. T.; Batchelor, J. F.; White, H. L. Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups J. Med. Chem. 1996, 39, 1857-1863
14. Riederer, P.; Danielczyk, W.; Grünblatt, E. Monoamine oxidase-B inhibition in Alzheimer's disease Neurotoxicology 2004, 25, 271-277
15. Finberg, J. P. M. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS neurotransmitters Pharmacol. Ther. 2014, 143, 133-152
16. Gura, T. Hope in Alzheimer's fight emerges from unexpected places Nature Med. 2008, 14, 894
17. Racchi, M.; Mazzucchelli, M.; Porrello, E.; Lanni, C.; Govoni, S. Acetylcholinesterase inhibitors: novel activities of old molecules Pharmacol. Res. 2004, 50, 441-451
18. Muñoz-Torrero, D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease Curr. Med. Chem. 2008, 15, 2433-2455
19. Castro, A.; Martínez, A. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors Curr. Pharm. Des. 2006, 12, 4377-4387
20. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases J. Med. Chem. 2008, 51, 347-372
21. León, R.; Garcia, A. G.; Marco-Contelles, J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease Med. Res. Rev. 2013, 33, 139-189
22. Anighoro, A.; Bajorath, J.; Rastelli, G. Polypharmacology: challenges and opportunities in drug discovery J. Med. Chem. 2014, 57, 7874-7887
23. 1-adrenoreceptors J. Med. Chem. 2003, 46, 4895-4903
24. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Roegler, C.; Deufel, T.; Fleck, C.; Peng, S.; Zhang, Y.; Lehmann, J. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates J. Med. Chem. 2008, 51, 713-716
25. Stosel, A.; Schlenk, M.; Hinz, S.; Kuppers, P.; Heer, J.; Gutschow, M.; Muller, C. E. Dual targeting of adenosine A2A receptors and monoamine oxidase B by 4 H -3,1-benzothiazin-4-ones J. Med. Chem. 2013, 56, 4580-4596
26. Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates Bioorg. Med. Lett. 2008, 18, 2905-2909
27. V. Pérez, V.; Marco, J. L.; Fernández-álvarez, E.; Unzeta, M. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition Br. J. Pharmacol. 1999, 127, 869-876
28. Bolea, I.; Gella, A.; Unzeta, M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors J. Neural. Transm. 2013, 120, 893-902
29. Bolea, I.; Juárez-Jiménez, J.; de los Ríos, C.; Chioua, M.; Pouplana, R.; Luque, F. J.; Unzeta, M.; Marco-Contelles, J.; Samadi, A. Synthesis, biological evaluation, and molecular modeling of donepezil and N -[(5-(benzyloxy)-1-methyl-1 H -indol-2-yl)methyl]- N -methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's Disease J. Med. Chem. 2011, 54, 8251-8270
30. Esteban, G.; Allan, J.; Samadi, A.; Mattevi, A.; Unzeta, M.; Marco-Contelles, J.; Binda, C.; Ramsay, R. R. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234 a multi-target compound for designed for use in Alzheimer's disease Biochim. Biophys. Acta, Proteins Proteomics 2014, 1844, 1104-1110
31. Bolea, I.; Gella, A.; Monjas, L.; Pérez, C.; Rodríguez-Franco, M. I.; Marco-Contelles, J. L.; Samadi, A.; Unzeta, M. The multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis Curr. Alzheimer Res. 2013, 9, 797-808
32. del Pino, J.; Ramos, E.; Bautista Aguilera, O. M.; Marco-Contelles, J.; Romero, A. Wnt signaling pathway, a potential target for Alzheimer's disease treatment, is activated by a novel multitarget compound ASS234 CNS Neurosci. Ther. 2014, 20, 568-570
33. Stasiak, A.; Mussur, M.; Unzeta, M.; Samadi, A.; Marco-Contelles, J. L.; Fogel, W. A. Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia Curr. Pharm. Des. 2014, 20, 161-171
34. Zhu, Z. J. 'Clik' assemby of selective inhibitors of MAO-A Bioorg. Med. Chem. Lett. 2010, 20, 6222-6225
35. Bautista-Aguilera, O. M.; Esteban, G.; Bolea, I.; Nikolic, K.; Agbaba, D.; Moraleda, I.; Iriepa, I.; Samadi, A.; Soriano, E.; Unzeta, M.; Marco-Contelles, J. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease Eur. J. Med. Chem. 2014, 75, 82-95
36. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Mikcolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; Toth, G.; Zagyva, A.; Zekany, A.; Finberg, J.; Lavian, G.; Gross, A.; Friedman, R.; Razin, M.; Huang, W.; Krais, B.; Chorev, M.; Youdim, M. B.; Weinstock, M. Novel dual inhibitors of AChE and MAO derived from hydroxyl aminoindan and phenethylamine as potential treatment for Alzheimer's disease J. Med. Chem. 2002, 54, 5260-5279
37. Zheng, H.; Youdim, M. B. H.; Fridkin, M. Site-activated multifunctional chelator with acetycholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's disease J. Med. Chem. 2009, 52, 4095-4098
38. Yogev-Falach, M.; Bar-Am, O.; Amit, T.; Weinreb, O.; Youdim, M. B. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing FASEB J. 2006, 20, 2177-2179
39. Youdim, M. B.; Weinstock, M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 Cell. Mol. Neurobiol. 2002, 21, 555-573
40. Ellman, G. L.; Courtney, K. D.; Andres, B. J.; Featherstone, R. M. A new and rapid colorimetric determination of acetylcholinesterase activity Biochem. Pharmacol. 1961, 7, 88
41. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis-and trans -resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity Biochem. Biophys. Res. Commun. 2006, 344, 688-695
42. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery; Wiley-Interscience: Hoboken, NJ, 2005.
43. Youdim, B. H. M.; Edmondson, D.; Tipton, K. F. The therapeutic potential of monoamine oxidase inhibitors Nature Rev. Neurosci. 2006, 7, 295-309
44. Palhagen, S.; Heinonen, E.; Hagglund, J.; Kaugesaar, T.; Maki-Ikola, O.; Palm, R. Selegiline slows the progression of the symptoms of Parkinson disease Neurology 2006, 66, 1200-1206
45. Lairez, O.; Calise, D.; Bianchi, P.; Ordener, C.; Spreux-Varoquaux, O.; Guilbeau-Frugier, C.; Escourrou, G.; Seif, I.; Roncalli, J.; Pizzinat, N.; Galinier, M.; Parini, A.; Mialet-Pérez, J. Genetic deletion of MAO-A promotes serotonin-dependent ventricular hypertrophy by pressure overload J. Mol. Cell Cardiol. 2009, 46, 587-95
46. Di Lisa, F.; Kaludercic, N.; Carpi, A.; Menabo, R.; Giogio, M. Mitochondrial pathways for ROS formation and myocardial injury: The relevance of p66She and monoamine oxidase Basic Res. Cardiol. 2009, 104, 131-139
47. Edmondson, D. E. Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: biological implications Curr. Pharm. Des. 2014, 20, 155-160
48. Finberg, J. P.; Gross, A.; Bar-Am, O.; Friedman, R.; Loboda, Y.; Youdim, M. B. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat Br. J. Pharmacol. 2006, 149, 647-656
49. Finberg, J. P.; Gillman, P. K. Selective inhibitors of monoamine oxidase Type B and the "cheese effect". In International Review of Neurobiology; Youdim, M. B.; Riederer, P., Eds.; Academic Press: Burlington, 2011; Vol. 100, pp 169-190.
50. Weinstock, M.; Gorodetsky, E.; Wang, R. H.; Gross, A.; Weinreb, O.; Youdim, M. B. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits Neuropharmacology 2002, 43, 999-1005
51. Yogev-Falach, M.; Bar-Am, O.; Amit, T.; Weinreb, O.; Youdim, M. B. H. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing FASEB J. 2006, 20, 2177-2179
52. Zheng, H.; Fridkin, M.; Youdim, M. B. H. Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease Neurochem. Res. 2010, 35, 2117-2123
53. Di, L.; Kerns, E. H.; Fan, K.; McConnell, O. J.; Carter, G. T. High throughput artificial membrane permeability assay for blood-brain barrier Eur. J. Med. Chem. 2003, 38, 223-232
54. Rodríguez-Franco, M. I.; Fernández-Bachiller, M. I.; Pérez, C.; Hernández-Ledesma, B.; Bartolomé, B. Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties J. Med. Chem. 2006, 49, 459-462
55. Fernández-Bachiller, M. I.; Pérez, C.; Monjas, L.; Rademann, J.; Rodríguez-Franco, M. I. New tacrine-4-oxo-4 H -chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and beta-amyloid-reducing properties J. Med. Chem. 2012, 55, 1303-1317
56. López-Iglesias, B.; Pérez, C.; Morales-García, J. A.; Alonso-Gil, S.; Pérez-Castillo, A.; Romero, A.; López, M. G.; Villarroya, M.; Conde, S.; Rodríguez-Franco, M. I. New melatonin- N, N -dibenzyl(N -methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease J. Med. Chem. 2014, 57, 3773-3785
57. Prati, F.; Uliassib, E.; Bolognesi, M. L. Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases Med. Chem. Commun. 2014, 5, 853-861